May 2017

Sun Mon Tue Wed Thu Fri Sat
  1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30 31      

« Physicians’ Use of Email With Patients: Factors Influencing Electronic Communication and Adherence to Best Practices | Main | GPs in the UK Dissatisfied with IT System »



Having been part in the testing of this product. I would say the answer is no to these questions. The online CPS is very nice, but too pricey. And the design is such that it takes a few too many clicks, more than necessary, to search for drugs.

Not mentioned in the article is that it also contains Therapeutic Choices, which is an excellent reference.

Dale Taylor

I just read that the Canadian Pharmaceutical Association has developed an e-therapeutics program ( ). The site provides prescribing information to assist healthcare members to make better drug decision choices. I note the program had 8.8 million dollars in Health Canada funding and was a collaboration between the pharmacists association nursing and Canadian Family practitioners.

I think an unbiased Canadian Drug information program is much needed for those of us using EMR's. My main complaint is that the cost of this program for individual users is $389 a year for individual users if combined with the electronic CPS or $225 for the e- therapeutics by itself. The government should be trying to distribute this program as cheaply as possible so as many doctors use it as possible to improve prescription decisions. Healthcare costs saved by reducing drug interactions, making more informed drug decisions and prescribing cheaper but equally effective drugs could save the system huge amounts of money. This is something I think the government should encourage to be integrated into our EMR's cheaply to promote its use. Most doctors are going to balk at putting out $389 every year in addition to their EMR leases. Epocrates is so popular because it allows us to check for drug interactions quickly on our handhelds at no cost. e-therapeutics on our computers could become as popular as epocrates if the price was more reasonable.

The comments to this entry are closed.